Literature DB >> 1167412

Multiple sclerosis and elevation of cerebrospinal fluid vaccinia virus antibody.

J A Thompson, P F Bray, L A Glasgow.   

Abstract

Thirty percent of 33 patients with a clinical diagnosis of multiple sclerosis and an elevation of cerebrospinal fluid (CSF) immunoglobulin G/albumin ratio greater than 2 standard deviations above the mean had elevation of the CSF vaccinia neutralizing antibody titer. Elevated titers were found in 1 of 23 patients with non-multiple sclerosis neurologic diseases and in none of the normal control patients. No linear correlation was found between the magnitude of the relative or absolute CSF immunoglobulin G concentration and the magnitude of the CSF vaccinia neutralizing antibody titers.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1167412     DOI: 10.1212/wnl.25.1.94

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Viral antibodies in cerebrospinal fluid of multiple sclerosis and control patients: comparison between radioimmunoassay and conventional techniques.

Authors:  B Forghani; N E Cremer; K P Johnson; A H Ginsberg; W H Likosky
Journal:  J Clin Microbiol       Date:  1978-01       Impact factor: 5.948

2.  Severe demyelinating diseases in childhood: a clinicopathological study.

Authors:  J M Adams
Journal:  J Natl Med Assoc       Date:  1978-03       Impact factor: 1.798

3.  [Tetanus antitoxin in serum and cerebral spinal fluid in viral meningitis in children (author's transl)].

Authors:  M Eibl; U Traugott; G Weippl; G Harasek
Journal:  Klin Wochenschr       Date:  1978-07-01

4.  The effect of levamisole on cellular immunity in multiple sclerosis.

Authors:  P C Dau; K P Johnson; L E Spitler
Journal:  Clin Exp Immunol       Date:  1976-11       Impact factor: 4.330

Review 5.  Does disease-irrelevant intrathecal synthesis in multiple sclerosis make sense in the light of tertiary lymphoid organs?

Authors:  Mickael Bonnan
Journal:  Front Neurol       Date:  2014-03-11       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.